FOR IMMEDIATE RELEASE
Orthomolecular Medicine News Service, October 31, 2008
Vitamin C Slows Cancer Down
And, Doctors Say, Can Reverse It
as Well
(OMNS, October 31, 2008) The BBC recently reported (1) that
"Vitamin C 'slows cancer growth.' An injection of a high dose of
vitamin C may be able to hold back the advance of cancers, US
scientists claim. The vitamin may start a destructive chain
reaction within the cancer cell." The injection "halved the
size" of tumors, and was reported in the Proceedings of the
National Academy of Sciences.
The study authors themselves said that daily, high-dose
vitamin C treatment "significantly decreased growth rates" of
ovarian, pancreatic, and malignant brain tumors in mice. Such
high, cancer-stopping levels of vitamin C can be "readily
achieved in humans given ascorbate intravenously." (2)
"Readily achieved"? Then this is important, absolutely vital
news for millions fighting or fearing cancer.
So what do major cancer organizations have to say? Not much.
That is disappointing, but hardly surprising. Both the American
Cancer Society and Cancer Research UK have downplayed or flatly
ignored decades of physician reports and controlled clinical
studies indicating that vitamin C stops cancer. What's worse,
each of these supposedly comprehensive cancer research and
education organizations continues to actively discourage people
from using vitamin C against cancer.
Look for yourself and see. The American Cancer Society's
vitamin C webpage (3) specifically states: "Although high does
of vitamin C have been suggested as a cancer treatment, the
available evidence from clinical trials has not shown any
benefit." And Cancer Research UK states that "There is currently
no evidence from clinical trials in humans that injecting or
consuming vitamin C is an effective way to treat cancer." (1)
"No benefit," they say. "No evidence," they say.
Both organizations are wrong. Neither statement is true.
In 2008, Korean doctors reported that intravenous vitamin C
"plays a crucial role in the suppression of proliferation of
several types of cancer," notably melanoma. (4)
In 2006, Canadian doctors reported on the effectiveness of
intravenous vitamin C in treating cancer. (5)
In 2004, doctors in America and Puerto Rico published
clinical cases of vitamin C successes against cancer. (6)
In 1990, American doctors published their results
successfully using vitamin C to treat kidney cancer (7). In 1995
and 1996, other cancers. (8) Using 30,000 mg of intravenous
vitamin C twice per week, they found that "metastatic lesions in
the lung and liver of a man with a primary renal cell carcinoma
disappeared in a matter of weeks. . . We subsequently reported a
case of resolution of bone metastases in a patient with primary
breast cancer [1A] using infusions of 100 grams, once or twice
per week." (9)
In 1982, Japanese doctors showed that vitamin C greatly
prolonged the lives of terminal cancer patients. (10)
And as early as 1976, over two decades ago, physicians in
Scotland showed that intravenous vitamin C improved quality and
length of life in terminal cancer patients. (11)
Why are ACS and Cancer Research UK oblivious to the weight of
evidence? All these previous clinical reports were published in
peer-reviewed medical journals. One may bear in mind that both
ACS and Cancer UK made their restrictive statements August 2008.
Yes, 2008. In spite of increasingly compelling evidence for 22
years, both the American Cancer Society and Cancer Research UK
are dragging their feet. Foot-dragging costs lives. Hundreds of
thousands of people have died from cancer that could have been
helped with ascorbate therapy. But for decades, their three
advocated cancer treatments have been "cut, zap, and drug":
surgery, radiation and chemotherapy. The use of high doses of
vitamins has been thoroughly excluded.
Indeed, ACS still says: "If a supplement is taken, the best
choice for most people is a balanced multivitamin/mineral
supplement that contains no more than 100% of the 'Daily Value'
of most nutrients." (3) That is harmful advice. Many well
designed clinical studies show that large doses of vitamin C and
other nutrients improve both quality and length of life for
cancer patients. The key is the use of sufficiently high
quantities, appropriately administered. More orange juice just
won't do it.
Cancer Research UK even maintains (1) that vitamin C "can
make cancer treatment less effective, reducing the benefits of
radiotherapy and chemotherapy." That statement is untrue.
(12,13) Oncologists routinely administer antioxidant drugs along
with chemotherapy with no diminution of effect. (14)
ACS and Cancer Research UK say that there is "no evidence
from clinical trials" that vitamin C is any good against cancer.
They should start reading the medical literature. They are way
behind the times. And they are wrong. Dead wrong.
References:
(1) BBC NEWS:
http://news.bbc.co.uk/go/pr/fr/-/2/hi/health/7540822.stm
Published: Aug 4, 2008.
(2) Chen Q, Espey MG, Sun AY, Pooput C, Kirk KL, Krishna MC,
Khosh DB, Drisko J, Levine M. Pharmacologic doses of ascorbate
act as a prooxidant and decrease growth of aggressive tumor
xenografts in mice. Proc Natl Acad Sci U S A. 2008 Aug 4.
(3)
http://www.cancer.org/docroot/ETO/content/ETO_5_3X_Vitamin_C.asp
(accessed Aug 12, 2008)
(4) Padayatty et al. Intravenously administered vitamin C as
cancer therapy: three cases. Canadian Medical Association
Journal, 2006. 174(7), March 28, p 937-942.
http://www.cmaj.ca/cgi/reprint/174/7/937
(5) Lee SK, Kang JS, Jung da J et al. Vitamin C suppresses
proliferation of the human melanoma cell SK-MEL-2 through the
inhibition of cyclooxygenase-2 (COX-2) expression and the
modulation of insulin-like growth factor II (IGF-II) production.
J Cell Physiol. 2008 Jul;216(1):180-8.
(6) Riordan HD, Riordan NH, Jackson JA, Casciari, J.J.,
Hunninghake, R, Gonzalez MJ, Mora, E.M., Miranda-Massari, J.R.,
Rosario, N., Rivera, A.: Intravenous Vitamin C as a Chemotherapy
Agent: a Report on Clinical Cases. Puerto Rico Health Sciences
J, June 2004, 23(2): 115-118.
(7) Riordan HD, Jackson JA, 'Schultz M. Case study: high-dose
intravenous vitamin C in the treatment of a patient with
adenocarcinoma of the kidney. J Ortho Med 1990; 5: 5-7.
(8) Riordan N, Jackson JA, Riordan HD. Intravenous vitamin C in
a terminal cancer patient. J Ortho Med 1996; 11: 80-82. Also:
Riordan, N. H., et al. (1995) Intravenous ascorbate as a tumor
cytotoxic chemotherapeutic agent. Medical Hypotheses, 44(3). p
207-213, March.
(9) Riordan NH, Riordan HD, Hunninghake RE. Intravenous
ascorbate as a chemotherapeutic and biologic response modifying
agent.
http://www.doctoryourself.com/riordan1.html and
http://www.canceraction.org.gg/recnac.htm . Additional
papers may be read at
http://brightspot.org/cresearch/index.shtml .
(10) Murata A, Morishige F and Yamaguchi H. (1982) Prolongation
of survival times of terminal cancer patients by administration
of large doses of ascorbate. International Journal of Vitamin
and Nutrition Research Suppl., 23, 1982, p. 103-113. Also in
Hanck, A., ed. (1982) Vitamin C: New Clinical Applications.
Bern: Huber, 103-113).
(11) Cameron E and Pauling L. (1976) Supplemental ascorbate in
the supportive treatment of cancer: prolongation of survival
times in terminal human cancer. Proceedings of the National
Academy of Sciences USA. 73:3685-3689. Also: Cameron E and
Pauling L. (1978) Supplemental ascorbate in the supportive
treatment of cancer: Reevaluation of prolongation of survival
times in terminal human cancer. Proceedings of the National
Academy of Sciences USA. 75:4538-4542. And: Cameron E and
Pauling L. (1981) Survival times of terminal lung cancer
patients treated with ascorbate. J. Intern. Acad. Prev. Med. 6:
21-27.
(12) Hoffer A. High doses of antioxidants including vitamin C do
not decrease the efficacy of chemotherapy. Townsend Letter for
Doctors and Patients.
http://www.doctoryourself.com/chemo.html
(13) Chemotherapy Doesn't Work, So Blame Vitamin C.
Orthomolecular Medicine News Service, October 7, 2008.
http://orthomolecular.org/resources/omns/v04n12.shtml
(14) Moss RW. Antioxidants against Cancer. Equinox Press Inc.
Brooklyn NY, 2000. ISBN-10: 1881025284; ISBN-13: 978-1881025283.
Also: Moss RW. Questioning Chemotherapy. Equinox Press, Brooklyn
NY, 1995. ISBN-10: 188102525X; ISBN-13: 978-1881025252.
For more information:
Intravenous vitamin C protocols for cancer treatment are posted
at:
http://www.doctoryourself.com/riordan1.html
http://www.canceraction.org.gg/recnac.htm
http://www.doctoryourself.com/cameron.html
Cameron E and Pauling L. Cancer and Vitamin C, revised edition.
Philadelphia: Camino Books, 1993. ISBN-10: 094015921X; ISBN-13:
978-0940159211
Hoffer A and Pauling L. Vitamin C and Cancer: Discovery,
Recovery, Controversy. Quarry Press, Kingston, ON, 1999. ISBN
1-55082-078-8 Reviewed at
http://www.doctoryourself.com/hoffer_vitc_can.html
Riordan HD, Hunninghake, R.E., Riordan NH, Jackson, J.J., Meng,
X.L., Taylor, P., Casciari, J.J., Gonzalez MJ, Miranda-Massari,
J.R., Mora, E.M., Norberto, R, Rivera, A. Intravenous Ascorbic
Acid: Protocol for its Application and Use. Puerto Rico Health
Sciences Journal, September 2003, 22:3.
Nutritional Medicine is Orthomolecular Medicine
Orthomolecular medicine uses safe, effective nutritional
therapy to fight illness. For more information:
http://www.orthomolecular.org
The peer-reviewed Orthomolecular Medicine News Service is a
non-profit and non-commercial informational resource.
Editorial Review Board:
Damien Downing, M.D.
Harold D. Foster, Ph.D.
Steve Hickey, Ph.D.
Abram Hoffer, M.D., Ph.D.
James A. Jackson, PhD
Bo H. Jonsson, MD, Ph.D
Thomas Levy, M.D., J.D.
Erik Paterson, M.D.
Gert E. Shuitemaker, Ph.D.
Andrew W. Saul, Ph.D., Editor and contact person. Email:
omns@orthomolecular.org
To Subscribe at no charge:
http://www.orthomolecular.org/subscribe.html
|